Search Results
Your search for The ASCO matches 21461 pages
Showing 16651 - 16700Nearly 800,000 Lung Cancer Deaths Averted during 1975–2000 Due to Decline in Smoking Rates
The cumulative impact of changes in smoking behavior that started in the mid-1950s averted approximately 795,851 U.S. lung cancer deaths, 552,574 among men and 243,277 among women from 1975 to 2000, according to a report in the Journal of the National Cancer Institute. The researchers also...
SIDEBAR: Could HPV Testing Be Used Alone?
“In the United States, there are no recommendations currently for HPV screening alone as a primary screening test for cervical cancer,” Michael L. LeFevre, MD, MSPH, Co-Vice Chair of the U.S. Preventive Services Task Force (USPSTF) told The ASCO Post. “Cytology picks up very few cases of...
New Guidelines Recommend Less Frequent Screening for Cervical Cancer, but That Doesn’t Mean Screening Is Less Important
In the News focuses on media reports that your patients may have questions about at their next visit. This continuing column will provide summaries of articles in the popular press that may prompt such questions, as well as comments from colleagues in the field. In March 2012, the U.S. Preventive...
Dr. Ronald D. Alvarez Elected 44th President of the Society of Gynecologic Oncology
Ronald D. Alvarez, MD, Professor and Director of the Division of Gynecologic Oncology at the University of Alabama at Birmingham, was elected the 44th President of the Society of Gynecologic Oncology at the society’s 43rd Annual Meeting on Women’s Cancer held March 24-27, 2012, in Austin, Texas....
Changing the Course of Human Health through Bold Pursuits in Science
The synergy between industry, academic research, and regulatory bodies will play an increasingly important role in ensuring the future of a robust cancer drug pipeline. To gain insight on oncologic development trends, The ASCO Post recently spoke with Jean Pierre Bizzari, MD, Head of Global...
Institute of Medicine Report on Omics-based Testing Bolsters ASCO’s Blueprint for Transforming Cancer Research
A recent report by the Institute of Medicine (IOM) addresses elements that ASCO has stated are necessary for transforming the therapeutic development and clinical trial processes. In March, the IOM released the report “Evolution of Translational Omics: Lessons Learned and the Path Forward,” which...
Constructing a Top Five List in Oncology
The American Society of Clinical Oncology has joined the American Board of Internal Medicine (ABIM) Foundation and eight other medical specialty societies to take a collective stand in improving patient care and addressing rising health-care costs. As part of the ABIM Foundation’s Choosing Wisely®...
ASCO Guidelines Support Weight-based Chemotherapy Dosing
The American Society of Clinical Oncology supports research showing that it’s safe and effective for people with cancer—especially those who are obese—to receive higher chemotherapy doses based not on estimates but on their actual weight. Direct your patients to ASCO’s guidelines on weight-based...
JCO Presents New Training Seminar for Authors
Journal of Clinical Oncology (JCO) recently launched a training seminar for potential authors, entitled, “Publishing Your Research: A Seminar From the Editors of JCO.” The first seminar was held in January prior to the 2012 Gastrointestinal Cancers Symposium in San Francisco. Daniel G. Haller, MD,...
FDA Approves Investigational New Drug Application for Clinical Testing of Oncology Drug Candidate ME-344
Marshall Edwards, Inc, an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced that it has received approval from the FDA of its Investigational New Drug (IND) application for ME-344, the Company’s lead mitochondrial inhibitor. The...
Expert Point of View: ColoPrint Gene Assay Can Guide Treatment Decisions in Stage II Colon Cancer
Axel Grothey, MD, of the Mayo Clinic, Rochester, Minnesota, told The ASCO Post that he finds the data “intriguing” and that the study exemplifies the value of developing molecular signatures for use in colon cancer. “It identifies patients with an excellent prognosis, who perhaps should not be...
ColoPrint Gene Assay Can Guide Treatment Decisions in Stage II Colon Cancer
ColoPrint, an 18-gene expression profile assay for patients with early-stage colon cancer, accurately stratifies patients by recurrence risk and identifies a subset who can be adequately treated by surgery alone, investigators reported at the 2012 Gastrointestinal Cancers Symposium.1 According to...
Novel Agents and Genomic Sequencing Show Promise in Improving Multiple Myeloma Management
For over 30 years, Kenneth C. Anderson, MD, Kraft Family Professor of Medicine at Harvard Medical School and Director of the Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics at Dana-Farber Cancer Institute in Boston, has focused his translational research on B-cell ...
Letter to the Editor: Patient Protection and Affordable Care Act Reconsidered
I read with interest the front-page interview of Dr. Ezekiel Emanuel by Jo Cavallo in the December 15, 2011, issue of The ASCO Post. Dr. Emanuel may have had some of the most prestigious positions in all of medicine, but his opinion of the Affordable Care Act is completely misguided. This...
Defining Meaningful Benefit: The Debate Continues in Bevacizumab’s Wake
The events surrounding the labeling of bevacizumab (Avastin) have been well covered since last November when the FDA withdrew the drug’s accelerated approval as a treatment for metastatic breast cancer. However, the controversy initiated a debate over the value of endpoints in clinical trials in...
2012 Oncology Meetings
MAY AUA Annual MeetingMay 19-23 • Atlanta, Georgia For more information: www.aua2012.org Keystone Symposia: The Role of Inflammation during CarcinogenesisMay 20-25 • Dublin, Ireland For more information: www.keystonesymposia.org JUNE Society for Immunotherapy of Cancer Primer on Tumor Immunology...
ASCO Continues to Support Oncologists in Electronic Health Records Adoption at 2012 Annual Meeting
As part of its ongoing effort to support oncology practices in adopting Electronic Health Records (EHR) to improve their quality of care, ASCO is holding its sixth annual EHR Vendor Lab, from June 2-4 at the 2012 ASCO Annual Meeting in Chicago. This resource gives attendees the opportunity to test...
Collaborating to Conquer Cancer, Theme of 2012 ASCO Annual Meeting
Developing curative regimens and other advances in pediatric oncology have demonstrated "what can be accomplished through collaboration, through the understanding of multidisciplinary care," said Michael P. Link, MD, ASCO President. Dr. Link commented to The ASCO Post about the theme for this...
SIDEBAR: Expect Questions from Your Patients
While the process of finding permanent solutions to the shortage of oncology drugs continues, physicians and patients may still face difficult situations when certain drugs, possibly part of curative regimens, are not available. “The key thing is that we urge patients to have discussions with...
SIDEBAR: Drug Development in the Era of Personalized Medicine
Advances in understanding cancer on a molecular level and the identification of subgroups of cancer patients with rare diseases are expected to have an effect on drug development and supply. “The vision of what cancer care will be like in the future is this very precise personalized care, where...
Update on Oncology Drug Shortage: Better for Now, But Permanent Solutions Must Address Underlying Issues
Over the past few years, drug shortages in the United States have been on the rise, involving hundreds of agents, many of which are lifesaving medications for patients with cancer. In recent months, the FDA has taken steps to alleviate some of the most critical oncology drug shortages. “We should...
Scott M. Lippman, MD, Named New Director of UC San Diego Moores Cancer Center
Scott M. Lippman, MD, has been named Director of Moores Cancer Center at the University of California, San Diego, effective May 1, 2012. Dr. Lippman was previously Chair of Thoracic/Head and Neck Medical Oncology at The University of Texas MD Anderson Cancer Center, in Houston. “As the new...
Oncology Professionals and Leaders to be Honored at ASCO Annual Meeting
ASCO is recognizing researchers, patient advocates, and leaders of the global oncology community through its Special Awards Program at this year’s Annual Meeting in Chicago. Recipients of ASCO’s special awards collectively represent significant strides in cancer treatment and leadership in the...
Fellows of the American Society of Clinical Oncology: 2012 Recipients Will be Honored at ASCO Annual Meeting
Formerly called the ASCO Statesman Award, which launched in 2007, the new distinction of Fellow of the American Society of Clinical Oncology (FASCO) is designed to honor ASCO’s most active volunteer members. “The FASCO status represents recognition for the most dedicated volunteer members inside...
Novel Initiative to Address Oncology Drug Crisis
Much has been written about the oncology drug shortage crisis in the United States. In the spirit of being part of the solution to that problem, a group of oncologists has formed the Citizen’s Oncology Foundation (COF). The goal of the start-up not-for-profit association is two-pronged: to find...
Brachytherapy Associated with Increased Complications Compared to Whole-breast Irradiation following Lumpectomy for Breast Cancer
Among older women with invasive breast cancer and treated with lumpectomy, brachytherapy compared with whole-breast irradiation was associated with a decreased likelihood of long-term breast preservation and an increased likelihood of complications, but no difference in overall survival, according...
ASCO President Michael P. Link, MD, Makes Statement on Passage of FDA Safety and Innovation Act
ASCO President Michael P. Link, MD, recently issued the following statement in response to the Senate Health, Education, Labor and Pensions Committee’s Passage of the FDA’s Safety and Innovation Act: “ASCO commends the Senate Health, Education, Labor and Pensions Committee for taking steps to...
Oncology Practices Recognized for Important Work in Clinical Trials
The Conquer Cancer Foundation of ASCO is recognizing six oncology practices from around the country for their work in improving access to clinical trials for patients in their communities. In addition, three ASCO State Affiliate societies are being honored for new projects that enhance cancer care...
State Oncology Societies Honored for Promising New Programs that Improve Patient Care
The State Affiliate Grant Program provides funding to ASCO State and Regional Affiliates to develop and implement new efforts that will lead to improved medical practice, collaboration, and research. ASCO’s State/Regional Affiliates are a vital resource for addressing issues of concern to the...
Geriatric Oncologists: A Small but Passionate Group
Although age is the major risk factor for developing cancer, geriatric oncology is still a relatively new discipline within the oncology community. To gain insight into this evolving component of cancer care, The ASCO Post recently spoke with a leader in the field, Stuart M. Lichtman, MD, FACP,...
Before Accepting a ‘Friend’ Request on Social Media, Carefully Consider the Potential Pitfalls and Perils
To friend or not to friend? That is the question many social networkers ponder daily. Oncologists and other health professionals considering “friend” requests from patients would be wise to first consider the potential pitfalls and perils of accepting such requests, according to an article written...
American Lung Association Provides Guidance on Lung Cancer Screening
The American Lung Association has released new interim guidelines to assist physicians, patients, and the public in their discussions about lung cancer screening. Developed by the American Lung Association’s Lung Cancer Screening Committee chaired by Jonathan Samet, MD, MS, from the University of...
New Research Shows Promise in Cachexia, a Persistent Clinical Challenge
In the late 1980s, researchers led by Alfred L. Goldberg, PhD, first isolated the large protein complexes now called 26S proteasomes, which are the sites where most cellular proteins are degraded back to amino acids. Protein degradation by the proteasome pathway is critical in regulating many...
FDA Strengthens Monitoring of Postapproval Drug Safety
A strengthened and modernized postmarket drug safety program has resulted in a substantial improvement in the FDA’s oversight of drugs once they reach the American public, according to a new report released by the agency’s Center for Drug Evaluation and Research (CDER). The report, Advances in...
FDA Reminds Public about Potential for Life-threatening Harm from Accidental Exposure to Fentanyl Patches
The FDA has issued a statement reminding patients, caregivers, and health-care professionals of the importance of appropriate storage, use, application, and disposal of fentanyl transdermal systems (including Duragesic and generic products) to prevent potential life-threatening harm from accidental ...
Automated HER2 Immunohistochemical System Approved
Leica Biosystems, a division of Leica Microsystems, announced that it has received premarket approval from the FDA for its Bond Oracle HER2 IHC System, a semi-quantitative immunohistochemical assay to determine human epidermal growth factor receptor 2 oncoprotein status in formalin-fixed,...
FDA Strengthens International Collaboration to Ensure Quality, Safety of Imported Products
FDA Commissioner Margaret A. Hamburg, MD, recently released the agency’s Global Engagement Report, detailing the many activities and strategies FDA is using to transform from a domestic to a global public health agency. The report describes the steps the agency is taking to ensure that imported...
Important Information Regarding Abstract Distribution for the 2012 ASCO Annual Meeting
ASCO has implemented a new abstract distribution model for its 2012 Annual Meeting to ensure simultaneous electronic and print release of important scientific information to attendees and the public. Plenary, Late-Breaking, and Clinical Review Abstracts (or Newly Released Abstracts, as they will be ...
Cancer.Net, ASCO’s Patient Education Website: Celebrating 10 Years of Trusted Cancer Education
“For 10 years, Cancer.Net has reflected the voice of the physician and given people with cancer and their loved ones the tools they need to actively participate in their cancer care. ASCO has used all the technological advances of the past decade to make information more accessible, interactive,...
ASCO Past President Highlights QOPI® Efforts to Improve Care in Michigan
ASCO’s Quality Oncology Practice Initiative (QOPI®) can be used to assess the quality of care in a statewide consortium of oncology practices and ultimately can lead to better care for patients with cancer, said ASCO Past President Douglas W. Blayney, MD, at a recent briefing on cancer care value...
ASCO Launches First Annual Quality Care Symposium November 30
So much health services research is underway in oncology that, rather than relegating it to just a portion of the Annual Meeting, ASCO has decided to launch a meeting devoted entirely to the emerging discipline. The first annual Quality Care Symposium will take place November 30 through December 1...
New Conquer Cancer Foundation of ASCO Professorship Focuses on Teaching Drug Development to Young Oncology Researchers
Despite a number of new drug approvals in 2011, there are still major challenges in developing effective oncology therapeutics and drug combinations that demonstrate significant survival advantages. Mechanisms are needed to ensure that the next generation of oncology researchers has the necessary...
New Video Series Addresses Challenges Facing Young Survivors
Cancer.Net has collaborated with LIVESTRONG to launch Moving Forward: Perspectives from Survivors and Doctors, a series of 13 videos focused on issues facing young adults with cancer. Topics covered include managing bills and expenses, dealing with the fear of recurrence, navigating the dating...
Conquer Cancer Foundation Board Member Tom Roberts Cites Need to Grow Research Capacity as Opportunity for Discovery Accelerates
Thomas G. Roberts, MD, dedicates a shelf in his home to memories of patients—photographs, notes, expressions of gratitude, traces of lives linked with his through cancer treatment. He looks at it every day, he says, and the memories inform his mission. “In oncology, you become part of people’s...
Expert Point of View: Biomarker Analysis of the TORCH Study: First-line Erlotinib Only in Patients with EGFR-positive Non–Small Cell Lung Cancer
Tetsuya Mitsudomi, MD, PhD, of Aichi Cancer Center Hospital in Nagoya, Japan, discussed the study presented by Tsao and colleagues1 and said that many previous trials have already shown that EGFR mutation is the most reliable predictive marker for treatment with EGFR tyrosine kinase inhibitors....
Biomarker Analysis of the TORCH Study: First-line Erlotinib Only in Patients with EGFR-positive Non–Small Cell Lung Cancer
Patients with advanced non–small cell lung cancer (NSCLC) should receive treatment with erlotinib (Tarceva) before receiving standard chemotherapy only if their tumor is known to harbor EGFR mutations, researchers reported at the 3rd European Lung Cancer Conference in Geneva, Switzerland.1 The...
Study Reports on New Potential Biomarker of Response in Lung Cancer Chemoprevention Studies
MiRNAs, negative post-transcriptional regulators of gene expression, are involved in bronchial carcinogenesis from the very early steps of this process. Endobronchial histology is currently considered as the best intermediate endpoint for chemoprevention studies. However, no intermediate biomarker...
Expert Point of View: New Genetic Signature May Help Identify Risk of Relapse in Patients with Completely Resected Early Non–Small Cell Lung Cancer
Commenting on the study, David Carbone, MD, PhD, of the Vanderbilt-Ingram Cancer Center, said that the Spanish group studied tumors from patients with completely resected stage I and II NSCLC for gene RNA expression profiles using 41,000 different probes. “Since over one-half of these patients...
New Genetic Signature May Help Identify Risk of Relapse in Patients with Completely Resected Early Non–Small Cell Lung Cancer
A new genetic signature identified by Spanish researchers may provide robust and objective information about which patients with completely resected early stage non-small cell lung cancer are at low or high risk of relapse following surgery, according to Florentino Hernando, MD, who presented the...
Cancer Care in India: Complex Challenges in a Populous Nation
With 1.22 billion people, India is the second most populous country in the world. Experts project that cancer incidence in India will increase by more than two-thirds over the next 20 years, to approximately 1.7 million new cases per year. Due to a range of economic and social issues, most of...
